Abstract: Acute kidney injury (AKI) is a common and serious dose-limiting complication of cisplatin chemotherapy. Cisplatin-induced AKI (CI-AKI) is initiated predominantly in proximal renal tubular epithelial cells (RTECs), where cisplatin enters through organic cation transporter 2 (OCT2) and copper transporter 1 (CTR1). This accumulation drives mitochondrial dysfunction, reactive oxygen species (ROS) overproduction, and the release of damage-associated molecular patterns (DAMPs). These signals activate key innate immune pathways, including Toll-like receptor 4/myeloid differentiation primary response 88/nuclear factor kappa B (TLR4/MyD88/NF-κB) signaling and the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, leading to a cytokine-driven inflammatory response. Macrophages are major infiltrating immune cells in CI-AKI: early M1 polarization amplifies tubular damage, whereas later M2-like macrophages support inflammation resolution and tissue repair. This review summarizes the mechanistic links between RTEC injury, innate immune activation, and RTEC–macrophage crosstalk, and highlights therapeutic opportunities such as TLR4/NF-κB blockade and modulation of macrophage polarization to reduce nephrotoxicity without compromising anticancer efficacy. Overall, an inflammation-centered view of RTEC–macrophage interactions may guide the development of effective renoprotective adjuncts for cisplatin-based regimens. Keywords: cisplatin, AKI, RTECs, macrophages, inflammation
Building similarity graph...
Analyzing shared references across papers
Loading...
Ping Tian
Rong Hu
MeiHao Xue
Journal of Inflammation Research
Building similarity graph...
Analyzing shared references across papers
Loading...
Tian et al. (Thu,) studied this question.
www.synapsesocial.com/papers/69a75e1cc6e9836116a287c6 — DOI: https://doi.org/10.2147/jir.s557661
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: